Deloitte Legal assists with the sale of Syndesi Therapeutics SA to AbbVie Central Finance B.V. 

Deloitte Legal is proud to have assisted the selling shareholders and the company with the sale of Syndesi Therapeutics SA to AbbVie Central Finance B.V.

Syndesi Therapeutics SA is a clinical stage biotechnology company, created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors, pioneering in the development of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118, which is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders.

With AbbVie’s acquisition of Syndesi Therapeutics SA, AbbVie aims to expand its neuroscience portfolio by advancing the research of a novel, first-in-class asset for the potential treatment of cognitive impairment.

The Deloitte Legal team comprised Christoph Michiels, Henri-Simon Vande Vyver and Jacques Bakulu.

Read the AbbVie press release here.